VERNON HILLS, Ill.--(BUSINESS WIRE)--Applied NeuroSolutions, Inc. (OTC BB:APNS)(www.appliedneurosolutions.com), a Company focused on the development of an integrated portfolio of products for the treatment and diagnosis of Alzheimer’s disease (AD), today reported that a peer-reviewed paper, "Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI,” is highlighted as a featured study in the December 11, 2007 issue of the print edition of Neurology. APNS’s p-tau 231 biomarker (p-tau 231) was utilized in an international, multicenter study, led by Dr. Harald Hampel, and shown to be a significant predictor of conversion in the transition from mild cognitive impairment (MCI) to Alzheimer's disease in a relatively short and clinically relevant observation interval.
